From Risk Factors to Systemic Disease: An Integrated Cardiovascular–Vascular Approach for Early Detection and Risk Management
DOI:
https://doi.org/10.64784/162Palavras-chave:
cardiovascular continuum, vascular disease, atherosclerosis, peripheral arterial disease, cardiovascular risk, polyvascular disease, early detection, integrated care, cardiology, angiologyResumo
Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, driven by complex interactions between metabolic, hemodynamic, and inflammatory factors. In recent years, the concept of the cardiovascular–vascular continuum has emerged as a comprehensive model that integrates cardiac and peripheral vascular diseases into a single systemic process. This review aims to analyze current evidence regarding this continuum, emphasizing the importance of early detection, global risk assessment, and coordinated management between cardiology and angiology. A structured narrative review was conducted using high-impact literature published from 2020 onward, including international clinical guidelines, randomized trials, and large observational studies. The analysis focused on the pathophysiology of atherosclerosis, the interaction of major cardiovascular risk factors, the clinical expression of disease across multiple vascular territories, and the implementation of integrated prevention and treatment strategies. The findings demonstrate that cardiovascular risk is cumulative and synergistic, with hypertension, dyslipidemia, diabetes mellitus, smoking, and obesity acting as central drivers of systemic vascular damage. Peripheral arterial disease and polyvascular involvement were identified as key markers of advanced atherosclerosis and increased risk of major adverse cardiovascular events. Additionally, the evidence supports the role of early detection strategies and multidisciplinary care models in improving clinical outcomes.
Referências
• Aboyans, V., Ricco, J. B., Bartelink, M. L. E. L., et al. (2020). ESC guidelines on peripheral arterial diseases. European Heart Journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455
• Anand, S. S., Bosch, J., Eikelboom, J. W., et al. (2020). Rivaroxaban plus aspirin in vascular disease. New England Journal of Medicine, 382(21), 1994–2004. https://doi.org/10.1056/NEJMoa2000052
• Arnett, D. K., Blumenthal, R. S., Albert, M. A., et al. (2020). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation, 141(16), e596–e646. https://doi.org/10.1161/CIR.0000000000000678
• Bauersachs, R., Zeymer, U., Brière, J. B., et al. (2021). Burden of coronary artery disease and PAD. European Heart Journal Supplements, 23(Suppl E), E5–E13. https://doi.org/10.1093/eurheartj/suab030
• Bhatt, D. L., Steg, P. G., Ohman, E. M., et al. (2020). International prevalence of cardiovascular risk factors in PAD. JAMA, 323(21), 2141–2150. https://doi.org/10.1001/jama.2020.1720
• Bonaca, M. P., & Creager, M. A. (2020). Peripheral artery disease and cardiovascular risk. Circulation Research, 126(12), 1813–1836. https://doi.org/10.1161/CIRCRESAHA.120.315844
• Gulati, M., Levy, P. D., Mukherjee, D., et al. (2021). 2021 AHA/ACC chest pain guideline. Circulation, 144(22), e368–e454. https://doi.org/10.1161/CIR.0000000000001029
• Knuuti, J., Wijns, W., Saraste, A., et al. (2020). ESC guidelines for chronic coronary syndromes. European Heart Journal, 41(3), 407–477. https://doi.org/10.1093/eurheartj/ehz425
• Libby, P., Buring, J. E., Badimon, L., et al. (2021). Atherosclerosis. Nature Reviews Disease Primers, 7(1), 1–21. https://doi.org/10.1038/s41572-021-00293-6
• Mach, F., Baigent, C., Catapano, A. L., et al. (2020). 2019 ESC/EAS guidelines for the management of dyslipidaemias. European Heart Journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455
• McDermott, M. M. (2021). Lower extremity PAD: contemporary management. JAMA, 325(21), 2188–2198. https://doi.org/10.1001/jama.2021.5487
• Nambi, V., & Ballantyne, C. M. (2021). Combination therapy for lipid lowering. Journal of the American College of Cardiology, 78(9), 933–935. https://doi.org/10.1016/j.jacc.2021.06.019
• Narula, J., Chandrashekhar, Y., & Braunwald, E. (2021). Time to add a new dimension to cardiovascular risk. Journal of the American College of Cardiology, 77(4), 391–394. https://doi.org/10.1016/j.jacc.2020.11.046
• Roth, G. A., Mensah, G. A., Johnson, C. O., et al. (2020). Global burden of cardiovascular diseases and risk factors, 1990–2019. Journal of the American College of Cardiology, 76(25), 2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010
• Timmis, A., Townsend, N., Gale, C., et al. (2022). European Society of Cardiology cardiovascular statistics 2021. European Heart Journal, 43(8), 716–799. https://doi.org/10.1093/eurheartj/ehab892
• Tsao, C. W., Aday, A. W., Almarzooq, Z. I., et al. (2022). Heart disease and stroke statistics—2022 update. Circulation, 145(8), e153–e639. https://doi.org/10.1161/CIR.0000000000001052
• Virani, S. S., Alonso, A., Aparicio, H. J., et al. (2021). Heart disease and stroke statistics—2021 update. Circulation, 143(8), e254–e743. https://doi.org/10.1161/CIR.0000000000000950
• Visseren, F. L. J., Mach, F., Smulders, Y. M., et al. (2021). 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 42(34), 3227–3337. https://doi.org/10.1093/eurheartj/ehab484
• Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2020). 2017 ACC/AHA hypertension guideline update. Hypertension, 71(6), e13–e115. https://doi.org/10.1161/HYP.0000000000000065
• Writing Committee Members, Heidenreich, P. A., Bozkurt, B., et al. (2022). 2022 AHA/ACC/HFSA heart failure guideline. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012
